Published in The BMJ · View the paper (DOI)
A study found that over half of cancer drugs approved through expedited pathways recover research and development costs within three years, despite lacking proof of added benefit. The researchers emphasize the need for better alignment between regulatory and reimbursement processes to promote effective drug development.
Coverage from 2 institutions